Related Experiment Videos
Update on hemangiomas of infancy
1Texas Children's Hospital, Baylor College of Medicine, Houston 77030-2399, USA. dmetry@bcm.tmc.edu
Current Opinion in Pediatrics
|July 27, 2004
Summary
Recent research advances understanding of infantile hemangiomas, linking them to placental tissue and identifying new markers. Morphology and location are key to assessing complication risks, with becaplermin gel showing promise for ulcer treatment.
Area of Science:
- Pediatric Dermatology
- Vascular Anomalies
- Developmental Biology
Background:
- Infantile hemangiomas (IH) are common benign vascular tumors in infants.
- Understanding the pathogenesis of IH is crucial for developing targeted therapies.
- Recent research has significantly improved our knowledge of IH.
Purpose of the Study:
- To review recent advances in the understanding of infantile hemangiomas.
- To highlight key findings in basic science and clinical research.
- To discuss implications for diagnosis, risk assessment, and treatment.
Main Methods:
- Review of recent clinical and basic science research on infantile hemangiomas.
- Analysis of new discoveries in IH etiology, markers, and therapeutic approaches.
Main Results:
- A link between infantile hemangiomas and placental tissue has been established.
- Unique immunohistochemical markers for IH have been identified.
- Morphology and location are critical for assessing complication risk.
- Becaplermin 1% gel demonstrates efficacy in treating refractory ulcerations.
Conclusions:
- The physical characteristics and site of an infantile hemangioma are vital for predicting potential complications.
- Ongoing research is advancing the understanding of IH causes, paving the way for new interventions and preventative strategies.